Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B

Lomitapide and Mipomersen

(2014) Daniel J. Rader et al.   CIRCULATION

Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects

(2014) Zhaoyang Li et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Lack of Clinical Pharmacodynamic and Pharmacokinetic Drug–Drug Interactions Between Warfarin and the Antisense Oligonucleotide Mipomersen

(2014) Zhaoyang Li et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces LDL-C in HoFH Pediatric Patients†

(2014) Sheryl Selvey et al.   Journal of Clinical Lipidology

Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo‐Controlled Study of Healthy Volunteers

(2014) JoAnn D. Flaim et al.   Journal of the American Heart Association

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

(2013) Mark J. Graham et al.   CIRCULATION RESEARCH

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

(2013) Raul D. Santos et al.   EUROPEAN HEART JOURNAL

Long Term Efficacy and Safety of Mipomersen During 4 Years of Treatment in a Cohort of Patients with Heterozygous Familial Hypercholesterolemia and Coronary Artery Disease (CAD)

(2013) P. Bart Duell et al.   Journal of Clinical Lipidology

JCL Roundtable: Drug treatment of severe forms of familial hypercholesterolemia

(2013) W. Virgil Brown et al.   Journal of Clinical Lipidology

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

(2013) Gregory S. Thomas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment

(2012) Frederick J. Raal et al.   ATHEROSCLEROSIS

Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B

(2012) Stanley T. Crooke et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Apolipoprotein B Synthesis Inhibition With Mipomersen in Heterozygous Familial Hypercholesterolemia

(2012) Evan A. Stein et al.   CIRCULATION

Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

(2012) Maartje E. Visser et al.   EUROPEAN HEART JOURNAL

Clinical pharmacokinetics of second generation antisense oligonucleotides

(2012) Rosie Z Yu et al.   Expert Opinion on Drug Metabolism & Toxicology

Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

(2012) S. Matthijs Boekholdt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease

(2012) Brian A. Ference et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Randomized, Placebo-Controlled Trial of Mipomersen in Patients with Severe Hypercholesterolemia Receiving Maximally Tolerated Lipid-Lowering Therapy

(2012) Mary P. McGowan et al.   PLoS One

A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans

(2012) Nicholas R Jones et al.   Molecular Therapy-Nucleic Acids

Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering Therapy

(2011) Frederick J. Raal et al.   CIRCULATION

A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk

(2011) Allan D. Sniderman et al.  

Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia

(2011) Fatima Akdim et al.   EUROPEAN HEART JOURNAL

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

(2011) Anne C. Goldberg et al.   Journal of Clinical Lipidology

Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia

(2010) Fatima Akdim et al.   AMERICAN JOURNAL OF CARDIOLOGY

RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform

(2010) C. Frank Bennett et al.   Annual Review of Pharmacology and Toxicology

Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy

(2010) Fatima Akdim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

In Vitro Metabolic Stabilities and Metabolism of 2′-O-(Methoxyethyl) Partially Modified Phosphorothioate Antisense Oligonucleotides in Preincubated Rat or Human Whole Liver Homogenates

(2010) Min-Son Baek et al.   OLIGONUCLEOTIDES

Antisense oligonucleotide pharmacokinetics and metabolism

(2009) Richard S Geary   Expert Opinion on Drug Metabolism & Toxicology

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100

(2008) Rosie Z. Yu et al.   BIOCHEMICAL PHARMACOLOGY

Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2′-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe

(2008) Rosie Z Yu et al.   CLINICAL PHARMACOKINETICS